Using the same molecular construction strategy, EMD Serono developed Hu14.18-IL2 (EMD 273063), which is composed of anti-GD2 antibody 14.18 and IL-2 molecule, and Phase I/II studies were performed to determine its effect on patients with recurrent melanoma (NCT00590824) (57) or with relapsed/refractory (R/R) neuroblastoma (NCT01334515) (58). Here, IL2 is linked to melanoma.